Delivering innovative therapeutic options to improve patient health.

Founded in 2010, Althera develops innovative patient focused medicines to improve patient health.

Our first product Rosuvastatin/Ezetimibe (AL-320) is available to patients in more than 28 countries worldwide including all major European markets.

Althera’s second product Ezetimibe/Atorvastatin tablets (AL-310), is approved in both US and Europe, and is expected to be available to patients in 2022/23.

Health Care

Life Sciences

Therapeutics

Althera

Org chart

Similar companies